Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Depreciation and Depletion (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Depreciation and Depletion for 4 consecutive years, with $300000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Depreciation and Depletion fell 66.67% year-over-year to $300000.0, compared with a TTM value of -$1.0 million through Sep 2025, down 132.26%, and an annual FY2024 reading of $900000.0, down 75.68% over the prior year.
  • Depreciation and Depletion was $300000.0 for Q1 2025 at Atara Biotherapeutics, up from -$1.3 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $1.5 million in Q1 2022 and bottomed at -$1.3 million in Q4 2024.
  • Average Depreciation and Depletion over 4 years is $730769.2, with a median of $900000.0 recorded in 2022.
  • The sharpest move saw Depreciation and Depletion changed 0.0% in 2023, then plummeted 244.44% in 2024.
  • Year by year, Depreciation and Depletion stood at $900000.0 in 2022, then changed by 0.0% to $900000.0 in 2023, then tumbled by 244.44% to -$1.3 million in 2024, then surged by 123.08% to $300000.0 in 2025.
  • Business Quant data shows Depreciation and Depletion for ATRA at $300000.0 in Q1 2025, -$1.3 million in Q4 2024, and $600000.0 in Q3 2024.